Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment

Background Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially renally cleared. We investigated the pharmacokinetics and safety of olaparib in patients with mild or moderate renal impairment to provide dosing recommendations.